A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

  • STATUS
    Not Recruiting
  • days left to enroll
    64
  • participants needed
    120
  • sponsor
    Genzyme, a Sanofi Company
Updated on 10 March 2021
Investigator
For site information, send an email with site number to
Primary Contact
Investigational Site Number 0140 (2.3 mi away) Contact
+93 other location
Factor VIII
hemophilia
factor ix
severe haemophilia a
antihemophilic factor
aln-at3sc
fitusiran

Summary

The purpose of this study is to determine the frequency of bleeding episodes in patients receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are assigned to continue with their regular medication. In addition, the study will assess safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).

Details
Condition Hemophilia A, Factor IX Deficiency, Hemophilia
Treatment fitusiran, factor VIII or factor IX
Clinical Study IdentifierNCT03417245
SponsorGenzyme, a Sanofi Company
Last Modified on10 March 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note